Pharmacokinetics of Melagatran and the Effect on Ex Vivo Coagulation Time in Orthopaedic Surgery Patients Receiving Subcutaneous Melagatran and Oral Ximelagatran: A Population Model Analysis

By Eriksson Ulf G.  

Clinical Pharmacokinetics, Vol. 42, Iss. 7, 2003-01 ,pp. : 687-701

Adis International

Access to resources Recommend Favorite

Influence of Severe Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Oral Ximelagatran and Subcutaneous Melagatran

By Eriksson U.G.  

Clinical Pharmacokinetics, Vol. 42, Iss. 8, 2003-01 ,pp. : 743-753

Adis International

Access to resources Recommend Favorite

Postoperative Melagatran/Ximelagatran for the Prevention of Venous Thromboembolism following Major Elective Orthopaedic Surgery: Effects of Timing of First Dose and Risk Factors for Thromboembolism and Bleeding Complications on Efficacy and Safety

By Ola E. Dahl  

Clinical Drug Investigation, Vol. 25, Iss. 1, 2005-01 ,pp. : 65-77

Adis International

Access to resources Recommend Favorite

Comparable Pharmacokinetics and Pharmacodynamics of Melagatran in Japanese and Caucasian Volunteers after Oral Administration of the Direct Thrombin Inhibitor Ximelagatran

By Wernevik Linda C.  

Clinical Pharmacokinetics, Vol. 45, Iss. 1, 2006-01 ,pp. : 85-94

Adis International

Access to resources Recommend Favorite

No Influence of Obesity on the Pharmacokinetics and Pharmacodynamics of Melagatran, the Active Form of the Oral Direct Thrombin Inhibitor Ximelagatran

By Sarich T.C.  

Clinical Pharmacokinetics, Vol. 42, Iss. 5, 2003-01 ,pp. : 485-492

Adis International

Access to resources Recommend Favorite